Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

DRCR.Net Aflibercept vs Bevacizumab + Aflibercept Différé pour le Traitement du CI-DME (DRCR AC)

9 septembre 2026 mis à jour par: Jaeb Center for Health Research

Essai randomisé comparant l'aflibercept intravitréen versus le bevacizumab intravitréen + l'aflibercept différé pour le traitement de l'œdème maculaire diabétique central

Both aflibercept and bevacizumab have been shown to improve vision in eyes with DME. In eyes with DME and at least moderate vision loss, both aflibercept and bevacizumab were also shown to be successful in many eyes. However, aflibercept was shown to be more effective at improving vision, on average, at 1 year and at 2 years. Due to the large cost difference between the two drugs, many clinicians and patients are choosing to initiate treatment with bevacizumab and then switch to aflibercept depending on the eye's response to bevacizumab treatment. However, there is no scientific evidence that this treatment strategy is as effective at improving vision as initiating treatment with aflibercept. Patients and clinicians do not know if this approach ultimately has deleterious effects on visual acuity. If starting with aflibercept is not better than starting with bevacizumab and switching to aflibercept if needed, the potential cost savings to future patients and the health care system would be substantial. However, if starting with aflibercept is better, then patients, clinicians, and health care providers can make informed decisions for how to best treat patients with DME and at least moderate vision loss.

Study Objectives To compare the efficacy of intravitreous aflibercept with intravitreous bevacizumab + deferred aflibercept if needed in eyes with CI DME and moderate vision loss

Aperçu de l'étude

Type d'étude

Interventionnel

Inscription (Réel)

270

Phase

  • Phase 3

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • California
      • Campbell, California, États-Unis, 95008
        • Retinal Diagnostic Center
      • Glendale, California, États-Unis, 91203
        • Macula & Retina Institute
      • Loma Linda, California, États-Unis, 92354
        • Loma Linda University Health Care, Department of Ophthalmology
      • Oakland, California, États-Unis, 94609-3028
        • East Bay Retina Consultants, Inc
    • Florida
      • Fort Myers, Florida, États-Unis, 33912
        • National Ophthalmic Research Institute
      • Jacksonville, Florida, États-Unis, 32216
        • Florida Retina Institute-Jacksonville
      • Lakeland, Florida, États-Unis, 33805
        • Florida Retina Consultants
      • Miami, Florida, États-Unis, 33126
        • Retina Macula Specialists of Miami
      • Orlando, Florida, États-Unis, 32806
        • Florida Retina Institute
      • Orlando, Florida, États-Unis, 32806
        • Central Florida Retina
      • Pinellas Park, Florida, États-Unis, 33782
        • Southeast Eye Institute, P.A. dba Eye Associates of Pinellas
      • Plantation, Florida, États-Unis, 33324
        • Fort Lauderdale Eye Institute
      • Sarasota, Florida, États-Unis, 34239
        • Sarasota Retina Institute
      • Sarasota, Florida, États-Unis, 34233
        • Retina Associates of Sarasota
      • Tampa, Florida, États-Unis, 33609
        • Retina Associates of Florida, LLC
      • Wesley Chapel, Florida, États-Unis, 33544
        • Retina Specialists of Tampa
    • Georgia
      • Augusta, Georgia, États-Unis, 30909
        • Southeast Retina Center, P.C.
      • Sandy Springs, Georgia, États-Unis, 30328
        • Thomas Eye Group
    • Illinois
      • Oak Park, Illinois, États-Unis, 60304
        • Illinois Retina Associates, S.C.
      • Springfield, Illinois, États-Unis, 62703
        • Springfield Clinic, LLP
    • Indiana
      • Indianapolis, Indiana, États-Unis, 46290
        • Raj K. Maturi, M.D., P.C.
      • New Albany, Indiana, États-Unis, 47150
        • John-Kenyon American Eye Institute
    • Kansas
      • Overland Park, Kansas, États-Unis, 66211
        • Mid-America Retina Consultants, P.A.
      • Shawnee Mission, Kansas, États-Unis, 66204
        • Retina Associates, P.A.
    • Kentucky
      • Paducah, Kentucky, États-Unis, 42001
        • Paducah Retinal Center
    • Louisiana
      • West Monroe, Louisiana, États-Unis, 71291
        • Eye Associates of Northeast Louisiana dba Haik Humble Eye Center
    • Maryland
      • Hagerstown, Maryland, États-Unis, 21740
        • Mid Atlantic Retina Specialists
    • Massachusetts
      • Ayer, Massachusetts, États-Unis, 01432
        • Valley Eye Physicians and Surgeons
      • Boston, Massachusetts, États-Unis, 02215
        • Joslin Diabetes Center
    • Michigan
      • Grand Rapids, Michigan, États-Unis, 49546
        • Vitreo-Retinal Associates
      • Grand Rapids, Michigan, États-Unis, 49546
        • Retina Specialists of Michigan
    • Missouri
      • St Louis, Missouri, États-Unis, 63128
        • The Retina Institute
    • New Mexico
      • Albuquerque, New Mexico, États-Unis, 87109
        • Eye Associates of New Mexico
    • New York
      • New York, New York, États-Unis, 10021
        • MaculaCare
      • Rochester, New York, États-Unis, 14620
        • Retina Associates of Western New York
    • North Carolina
      • Asheville, North Carolina, États-Unis, 28803
        • Western Carolina Clinical Research, LLC
      • Charlotte, North Carolina, États-Unis, 28210
        • Charlotte Eye, Ear, Nose and Throat Assoc., PA
    • Ohio
      • Cleveland, Ohio, États-Unis, 44106
        • University Hospitals Cleveland Medical Center
    • Oklahoma
      • Oklahoma City, Oklahoma, États-Unis, 73104
        • Dean A. McGee Eye Institute
    • Oregon
      • Portland, Oregon, États-Unis, 97221
        • Retina Northwest, PC
      • Springfield, Oregon, États-Unis, 97477
        • Cascade Medical Research Institute, LLC
    • Pennsylvania
      • Monroeville, Pennsylvania, États-Unis, 15146
        • Retina Vitreous Consultants
      • Philadelphia, Pennsylvania, États-Unis, 19107-5109
        • Retinavitreous Associates, dba; Mid Atlantic Retina
    • Tennessee
      • Knoxville, Tennessee, États-Unis, 37909
        • Southeastern Retina Associates, P.C.
    • Texas
      • Austin, Texas, États-Unis, 78705
        • Austin Retina Associates
      • Austin, Texas, États-Unis, 78705
        • Retina Research Center
      • Grapevine, Texas, États-Unis, 76051
        • Retina Center of Texas
      • Houston, Texas, États-Unis, 77030
        • Retina Consultants of Houston, PA
      • Houston, Texas, États-Unis, 77030
        • Baylor Eye Physicians and Surgeons
      • Lubbock, Texas, États-Unis, 79424
        • Texas Retina Associates
      • McAllen, Texas, États-Unis, 78503
        • Valley Retina Institute
      • San Antonio, Texas, États-Unis, 78240
        • Retinal Consultants of San Antonio
    • Washington
      • Spokane, Washington, États-Unis, 99204
        • Spokane Eye Clinic
    • Wisconsin
      • Milwaukee, Wisconsin, États-Unis, 53226
        • Medical College of Wisconsin

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Participant-level Criteria Inclusion

To be eligible, the following inclusion criteria must be met:

  1. Age ≥ 18 years • Individuals <18 years old are not being included because DME is so rare in this age group that the diagnosis of DME may be questionable.

  2. Diagnosis of diabetes mellitus (type 1 or type 2)

    • Any one of the following will be considered to be sufficient evidence that diabetes is present:

    Current regular use of insulin for the treatment of diabetes Current regular use of oral anti-hyperglycemia agents for the treatment of diabetes Documented diabetes by American Diabetes Association and/or World Health Organization criteria

  3. At least one eye meets the study eye criteria listed.

  4. Able and willing to provide informed consent.

    Exclusion

    An individual is not eligible if any of the following exclusion criteria are present:

  5. Significant renal disease, defined as a history of chronic renal failure requiring dialysis or kidney transplant.

  6. A condition that, in the opinion of the investigator, would preclude participation in the study (e.g., unstable medical status including blood pressure, cardiovascular disease, and glycemic control).

    • Individuals in poor glycemic control who, within the last four months, initiated intensive insulin treatment (a pump or multiple daily injections) or plan to do so in the next four months should not be enrolled.
  7. Participation in an investigational trial within 30 days of randomization that involved treatment with any drug that has not received regulatory approval for the indication being studied at the time of study entry.

    • Note: study participants cannot receive another investigational drug while participating in the study.

  8. Known allergy to any component of the study drug or any drug used in the injection prep (including povidone iodine prep).

  9. Blood pressure > 180/110 (systolic above 180 OR diastolic above 110).

    • If blood pressure is brought below 180/110 by anti-hypertensive treatment, individual can become eligible.

  10. Systemic anti-VEGF or pro-VEGF treatment within four months prior to randomization or anticipated use during the study.

    • These drugs cannot be used during the study.

  11. For women of child-bearing potential: pregnant or lactating or intending to become pregnant within the next 24 months.

    • Women who are potential study participants should be questioned about the potential for pregnancy. Investigator judgment is used to determine when a pregnancy test is needed.

  12. Individual is expecting to move out of the area of the clinical center to an area not covered by another clinical center during the next two years.

Study Eye Criteria The study participant must have at least one eye meeting all of the inclusion criteria and none of the exclusion criteria listed below.

Study participants can have two study eyes only if both eyes are eligible at the time of randomization. For study participants with two eligible eyes, the logistical complexities of the protocol must be considered for each individual prior to randomizing both eyes.

The eligibility criteria for a study eye are as follows:

Inclusion

  1. Best corrected Electronic-Early Treatment Diabetic Retinopathy Study visual acuity letter score < 69 (i.e., 20/50 or worse) and ≥ 24 (i.e., 20/320 or better) within eight days of randomization.

  2. On clinical exam, definite retinal thickening due to diabetic macular edema involving the center of the macula.

  3. Diabetic macular edema present on optical coherence tomography (OCT) within eight days of randomization

    • Zeiss Cirrus central subfield: ≥ 290µm in women or ≥ 305µm in men
    • Heidelberg Spectralis central subfield: ≥ 305µm in women or ≥ 320µm in men
    • Investigator must verify accuracy of OCT scan by ensuring it is centered and of adequate quality
  4. Media clarity, pupillary dilation, and individual cooperation sufficient for adequate fundus photographs.

    Exclusions

    The following exclusions apply to the study eye only (i.e., they may be present for the nonstudy eye):

  5. Macular edema is considered to be due to a cause other than diabetic macular edema.

    • An eye should not be considered eligible if: (1) the macular edema is considered to be related to ocular surgery such as cataract extraction or (2) clinical exam and/or OCT suggest that vitreoretinal interface abnormalities (e.g., a taut posterior hyaloid or epiretinal membrane) are the primary cause of the macular edema.

  6. An ocular condition is present such that, in the opinion of the investigator, visual acuity loss would not improve from resolution of macular edema (e.g., foveal atrophy, pigment abnormalities, dense subfoveal hard exudates, nonretinal condition).

  7. An ocular condition is present (other than diabetes) that, in the opinion of the investigator, might affect macular edema or alter visual acuity during the course of the study (e.g., vein occlusion, uveitis or other ocular inflammatory disease, neovascular glaucoma, etc.).

  8. Substantial cataract that, in the opinion of the investigator, is likely to be decreasing visual acuity by three lines or more (i.e., cataract would be reducing acuity to 20/40 or worse if eye was otherwise normal).

  9. History of an anti-vascular endothelial growth factor (anti-VEGF) treatment for diabetic macular edema (DME) in the past 12 months or history of any other treatment for DME at any time in the past four months (such as focal/grid macular photocoagulation, intravitreous or peribulbar corticosteroids).

    • Enrollment will be limited to a maximum of 25% of the planned sample size with any history of anti-VEGF treatment for DME. Once this number of eyes has been enrolled, any history of anti-VEGF treatment for DME will be an exclusion criterion.

  10. History of pan-retinal photocoagulation within four months prior to randomization or anticipated need for pan-retinal photocoagulation in the six months following randomization.

  11. History of anti-VEGF treatment for a disease other than DME in the past 12 months.

  12. History of major ocular surgery (including vitrectomy, cataract extraction, scleral buckle, any intraocular surgery, etc.) within prior four months or anticipated within the next six months following randomization.

  13. History of YAG capsulotomy performed within two months prior to randomization.

  14. Aphakia.

  15. Exam evidence of external ocular infection, including conjunctivitis, chalazion, or significant blepharitis.

  16. Evidence of uncontrolled glaucoma. • Intraocular pressure must be <30, with no more than one topical glaucoma medication, and no documented glaucomatous field loss for the eye to be eligible

Note, combination therapies are considered more than one medication

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Double

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Comparateur actif: Aflibercept Group

2.0 mg intravitreous aflibercept

Intravitreous aflibercept injection is made by Regeneron Pharmaceuticals, Inc. and is approved by the FDA for the treatment of neovascular age-related macular degeneration, macular edema due to central retinal vein occlusion, macular edema due to branch retinal vein occlusion, diabetic macular edema, and diabetic retinopathy in eyes with diabetic macular edema.

Study eyes assigned to receive aflibercept will receive a dose of 2.0 mg in 0.05 cc. Aflibercept will be obtained commercially by the clinical site. The physical, chemical, and pharmaceutical properties and formulation of aflibercept are provided in the Package Insert.

Intravitreous Injection Technique The injection is preceded by a povidone iodine prep of the conjunctiva. In general, topical antibiotics in the pre-, peri-, or post-injection period should not be used.

The injection will be performed using sterile technique

Autres noms:
  • Eylea
Expérimental: Bevacizumab + Deferred Aflibercept Group

1.25 mg intravitreous bevacizumab + deferred intravitreous 2.0 mg aflibercept if eye meets switch criteria

Intravitreous aflibercept injection is made by Regeneron Pharmaceuticals, Inc. and is approved by the FDA for the treatment of neovascular age-related macular degeneration, macular edema due to central retinal vein occlusion, macular edema due to branch retinal vein occlusion, diabetic macular edema, and diabetic retinopathy in eyes with diabetic macular edema.

Study eyes assigned to receive aflibercept will receive a dose of 2.0 mg in 0.05 cc. Aflibercept will be obtained commercially by the clinical site. The physical, chemical, and pharmaceutical properties and formulation of aflibercept are provided in the Package Insert.

Intravitreous Injection Technique The injection is preceded by a povidone iodine prep of the conjunctiva. In general, topical antibiotics in the pre-, peri-, or post-injection period should not be used.

The injection will be performed using sterile technique

Autres noms:
  • Eylea

Bevacizumab is made by Genentech, Inc. and is approved by the FDA for the treatment of metastatic colorectal cancer as well as the treatment of non-squamous non-small cell lung cancer, glioblastoma, and metastatic renal cell carcinoma.

Study eyes assigned to receive bevacizumab will receive a dose of 1.25 mg provided by a single compounding pharmacy identified by the Network and distributed by the Network. The volume of the injections will be 0.05 cc.

Intravitreous injection technique: The injection is preceded by a povidone iodine prep of the conjunctiva. In general, topical antibiotics in the pre-, peri-, or post-injection period should not be used.

The injection will be performed using a sterile technique.

Autres noms:
  • Avastin

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Mean Change in Visual Acuity
Délai: 2 years

Area under the curve mean change in the electronic early treatment diabetic retinopathy study visual acuity. Visual acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study visual-acuity test on a scale from 100 letters (Snellen equivalent, 20/10) to 0 letters (Snellen equivalent, <20/800), with higher scores indicating better vision. The data presented are the best-corrected visual acuity in the study eye after protocol-defined refraction. The primary outcome was the time-averaged change in the visual-acuity letter score over a period of 104 weeks. The score was derived by calculating the area under the curve (AUC) over the 104-week period for the change in visual acuity from baseline and dividing by the length of follow-up.

2 years

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Nombre de visites
Délai: 2 ans
2 ans
Nombre d'yeux dans le groupe Bevacizumab-first répondant aux critères de changement
Délai: Base de référence à 12 semaines
Base de référence à 12 semaines
Nombre d'yeux dans le groupe Bevacizumab-first répondant aux critères de changement
Délai: Base de référence à 24 semaines
Base de référence à 24 semaines
Nombre d'yeux dans le groupe Bevacizumab-first répondant aux critères de changement
Délai: Base de référence à 52 semaines
Base de référence à 52 semaines
Nombre d'yeux dans le groupe Bevacizumab-first répondant aux critères de changement
Délai: Base de référence à 104 semaines
Base de référence à 104 semaines
Change in Visual Acuity From Baseline
Délai: 2 years

Visual acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study visual-acuity test on a scale from 100 letters (Snellen equivalent, 20/10) to 0 letters (Snellen equivalent, <20/800), with higher scores indicating better vision.

2 years
Increase in E-ETDRS Visual Acuity Letter Score
Délai: 2 years

Visual acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study (E-ETDRS) visual-acuity test on a scale from 100 letters (Snellen equivalent, 20/10) to 0 letters (Snellen equivalent, <20/800), with higher scores indicating better vision.

2 years
Decrease in E-ETDRS Visual Acuity Letter Score
Délai: 2 years

Visual acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study visual-acuity test on a scale from 100 letters (Snellen equivalent, 20/10) to 0 letters (Snellen equivalent, <20/800), with higher scores indicating better vision.

2 years
Visual Acuity
Délai: 2 years

Visual acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study visual-acuity test on a scale from 100 letters (Snellen equivalent, 20/10) to 0 letters (Snellen equivalent, <20/800), with higher scores indicating better vision.

2 years
Optical Coherence Tomography Central Subfield Thickness Change From Baseline
Délai: 2 years

Measurements made on the Cirrus device were converted to equivalent scores as would be assessed on the Spectralis device with the use of the following formula: Spectralis score = 40.78 + 0.95 × Cirrus score.

2 years
Optical Coherence Tomography Central Subfield Thickness Below the Sex-specific Threshold for Central-involved Diabetic Macular Edema
Délai: 2 years

Optical coherence tomography (OCT) central subfield thickness equivalents for measurements obtained on Spectral domain OCT machines were 320 μm for men and 305 μm for women on the Spectralis device (Heidelberg) and were 305 μm and 290 μm, respectively on the Cirrus OCT measurement device (Zeiss).

2 years
Number of Injections
Délai: 2 years

All study injections were counted, including aflibercept injections received among eyes in the bevacizumab first group.

2 years

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

7 décembre 2017

Achèvement primaire (Réel)

22 décembre 2021

Achèvement de l'étude (Réel)

22 décembre 2021

Dates d'inscription aux études

Première soumission

23 octobre 2017

Première soumission répondant aux critères de contrôle qualité

23 octobre 2017

Première publication (Réel)

25 octobre 2017

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

1 octobre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

9 septembre 2026

Dernière vérification

1 septembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

produit fabriqué et exporté des États-Unis.

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner